Evgen Pharma Share Price (EVG)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Evgen Pharma	LSE:EVG	London	Ordinary Share	GB00BSVYN304	ORD 0.25P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	-0.50p	-2.25%	21.70p	980,802	14:00:55

Bid Price		Offer Price	High Price	Low Price	Open Price
21.00p		22.40p	23.20p	20.50p	21.70p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology		-3.03	-3.28		21.5

Related Shares
AstraZeneca (AZN), GlaxoSmithKline (GSK), Venn Life (VENN), Port Erin (PEBI)

Evgen Pharma (EVG) Latest News

Evgen Pharma News

Date	Time	Source	Headline
18/3/2019	14:01	UKREG	Evgen Pharma PLC Price Monitoring Extension
18/3/2019	11:10	ALNC	Evgen Pharma Expects STEM Trial Read-Out Next Week
18/3/2019	07:35	ALNCF	Alliance News Flash Headline
18/3/2019	07:01	UKREG	Evgen Pharma PLC Update on SFX-01 trial read-out dates
05/3/2019	11:35	ALNC	Study Of Evgen Pharma's SFX-01 Multiple Sclerosis Drug Shows Promise
05/3/2019	07:00	UKREG	Evgen Pharma PLC SFX-01 data published in peer reviewed journal
06/2/2019	15:30	UKREG	Evgen Pharma PLC Holding(s) in Company
05/2/2019	09:18	ALNC	Evgen Pharma Finishes Patient Recruitment For Stroke Treatment Trial
05/2/2019	07:00	UKREG	Evgen Pharma PLC Clinical trial update confirms read-outs on track
30/1/2019	17:28	UKREG	Evgen Pharma PLC Grant of Options

More Evgen Pharma News

Evgen Pharma Takeover Rumours

Evgen Pharma (EVG) Share Charts

1 Year Evgen Pharma Chart

1 Month Evgen Pharma Chart

Intraday Evgen Pharma Chart

Evgen Pharma (EVG) Discussions and Chat

Evgen Pharma Forums and Chat

Date	Time	Title	Posts
21/3/2019	19:02	Evgen Pharma: Developing Sulforaphane to treat Stroke, MS and Cancer	972
17/6/2018	14:42	Interview and Q&A with Evgen Pharma	2
26/6/2017	06:38	Evgen Pharma Plc Investor Presentation	-
13/6/2017	08:45	Evgen Pharma Interview	-
29/11/2016	08:27	Evgen Pharma (EVG) chief executive Stephen Franklin	39

Add a New Thread

Evgen Pharma (EVG) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
2019-03-21 18:27:40	21.25	75,000	15,937.50	O
2019-03-21 17:24:35	21.10	100,000	21,100.00	O
2019-03-21 17:24:09	21.10	100,000	21,100.00	O
2019-03-21 15:28:32	22.10	371	81.99	O
2019-03-21 15:18:27	22.16	3,500	775.60	O

View all Evgen Pharma trades in real-time

Evgen Pharma (EVG) Top Chat Posts

Date	Subject
21/3/2019 08:20	Evgen Pharma Daily Update: Evgen Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 22.20p. Evgen Pharma has a 4 week average price of 14.75p and a 12 week average price of 14.75p. The 1 year high share price is 27.80p while the 1 year low share price is currently 12.25p. There are currently 98,912,416 shares in issue and the average daily traded volume is 349,524 shares. The market capitalisation of Evgen Pharma is £21,463,994.27. Read Full Thread Reply
19/3/2019 08:09	soultrading: The share price here could explode upwards. Everything seems to sound very positive indeed. Read Full Thread Follow Reply
06/3/2019 19:25	l0ngterm: The ceo has said repeatedly let the science do the talking, not the PR team. So investors that look for news will get bored, chase something else etc. Others were expecting a spike or rise into the results. So not really surprised at where we are from a share price perspective. Read Full Thread Follow Reply
02/1/2019 17:00	timbo003: >>>spmc, had the response rate been 30%, I suspect the share price would be multiples of where it is now, I am quite happy with where the price is now, as it provides an opportunity to top up at a price which does not really reflect the risk reward profile IMO >>>>>aoifesweb, as a Surrey based shareholder, I think it was probably beyond the call of duty to attend an AGM in Manchester, especially as the Research Symposium was due to be held in London a couple of months after the AGM. Read Full Thread Follow Reply
02/1/2019 15:13	spmc: You can tell the 20% we hit on the interim update wasn’t considered good enough by the way the share price reacted. We dropped from 25.3p down to 17p. The market know’s the margins are so fine now it’s basicaly a coin toss for the final readout. I would have been much happier if their had been 30% plus responders as there would now be more room for error. Read Full Thread Follow Reply
13/11/2018 10:52	aoifesweb: This is my favourite bit ‘Analysts at Northland Capital currently have a price target of 113p on the shares, providing over 500% upside from today’s share price. The global market opportunity in metastatic breast cancer alone for SFX-01 is estimated to be between US$6 to US$7bn/year, with this in mind it’s easy to see why analysts expect the shares perform so well.‘: Https://uk-investor.com/2018/11/12/could-evgen-pharma-lonevg-make-you-a-millionaire-in-2019/ Read Full Thread Follow Reply
18/9/2018 11:27	pdt: I see the slide sets are now online on the Evgen website. Lots of information. Good to see confirmation that we should get pre-clinical data on Stroke, Autism and Triple Negative Breast Cancer in Q4. The news on TNBC looks like it will be positive since the slide set about STEM indicated that SFX-01 worked in a similar way with TNBC. Also in the patient 1 case study it looks like another person's disease has been stabilised for at least 16 months from May 17 to Sept 18 (latest scan). All looks very positive to me but perhaps that will not be reflected in the share price until we have a positive phase II result ?? Read Full Thread Follow Reply
13/6/2018 11:14	teddy boy1: There should be a law against what has happened this morning ;the way the share price was systematically taken down to encourage more sales.This share is definitely being "worked " and the bottom line is that all the shorters and the market makers have made themselves a shed load of money over the past 3 days- and this is on a GOOD trial update ! Think of what would have happened if the news had been bad! On second thoughts the share price would not have been too much different ,left to its own devices. Anyhow this is AIM , and this is how things are ! Perhaps companys such as EVGEN and IDP with very tightly held shares should be avoided like the plague as they are prime candidates for manipulation . With such companys;until they have proved themselves 100 per cent, the seeds of doubt will be sown and before we know where we are the share price has been worked down until the share price bears no resemblance to its true value. This is a real pity as I have not read anything myself which would encourage me to dispose of my shares as, as far as I am concerned ,Evgen Pharma has a very bright future .However ,it could still be many months/years before we are allowed a TRUE share price which values the company for what it is worth and not what some individuals CAUSE it to be, in the quest to make some easy money for themselves, over and over again! Anyone else agree with my sentiments? Read Full Thread Follow Reply
12/6/2018 10:48	teddy boy1: Still a decent amount of buying going on so it seems that there are many who have "kept the faith", which in the light of the trial update is not too surprising. It is clear to me that the share price was stepped down yesterday by the market makers in order to try and sow doubt so that they could accumulate some more of these tightly held shares. Within the next day or two the process will be reversed. The share price will be stepped up at the beginning of the day and this will attract buyers. How do I know.?- because this process is being repeated again and again on shares such as this.! The bottom line is that the update reads very well and gives encouragement to the company to plough ahead to demonstrate to all concerned that they have a winner on their hands.This is ,of course , assuming that they do not get taken out before very long by one of the big pharmas who will be able to see that this treatment definitely "has legs" and consequently could, in time, be a useful and profitable addition to their portfolio WATCH THIS SPACE! Read Full Thread Follow Reply
11/6/2018 18:57	teddy boy1: It is pleasing to see that Northland Capital having seen the trial update,are still of the opinion that the share price target should remain unchanged at 113P. In my opinion there has been a certain amount of share price manipulation to-day as there has been more buying than selling. If past experience is anything to go by, I will be very surprised if the price does not show a nice "correction" tomorrow. Things are still on course for Evgen although it will be another 6 months before this has been one hundred per cent proved. In the meantime I am still more that happy to have this share in my portfolio! Read Full Thread Follow Reply
03/5/2018 14:04	bernymadoff: Only idiots look at the rise and fall of a share price to determine whether they should invest and at what price. It wasn't long ago that institutions were paying 37p on IPO to get exposure to the drugs EVG are testing. Since then many of them have continued to buy and they currently hold 55% or so of the whole company. Institutional investment is one of the major ingredients I look for when deciding to invest anywhere. It gives you a level of confidence knowing that experts have evaluated the company to a degree that lay people could not achieve. Big plus there. Then there is the performance of the company. To date EVG have not put a foot wrong and all their drug trials have exceeded market expectations. Yet the market has not assigned any value to the progress the company has made since IPO in October 2015. Like many other pre-revenue AIM companies with great potential it has been at the mercy of the spivs in the city who have manipulated the share price down so that they can screw the company in the knowledge that it is dependent on placings to see it through to commercialisation. There is a wealth of information out there showing just how disconnected the share price is to the actual potential of EVG. For me that's where the opportunity lies. The greater the disconnect the greater the correction (in fact in these cases the correction often overshoots to the overvalued side). The other big thing the company has going for it is that it is funded through to the end of the year by which point it may well have landed a licensing or JV deal if the results due this quarter and then again at the end of the year are any good. Certainly the CEO has been dropping hints to that effect in recent rns'. You can choose to play the swings or you can hold for the big prize that the evidence suggests is now within grasp. Read Full Thread Follow Reply

Evgen Pharma share price data is direct from the London Stock Exchange

Your Recent History

LSE

EVG

Evgen Phar..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P: V: D:20190322 04:40:29